Tekmira Pharmaceuticals Corporation  

(Public, NASDAQ:TKMR)   Watch this stock  
Find more results for TKMR
16.00
-0.11 (-0.68%)
Nov 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.97 - 16.30
52 week 7.17 - 31.48
Open 16.24
Vol / Avg. 356,913.00/1.71M
Mkt cap 359.48M
P/E     -
Div/yield     -
EPS -1.48
Shares 22.31M
Beta 1.18
Inst. own     -
Nov 21, 2014
Tekmira Pharmaceuticals Corp Analyst and Investor Day
Nov 19, 2014
Tekmira Pharmaceuticals Corp at Stifel Healthcare Conference
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Call
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Release
Oct 7, 2014
Tekmira Pharmaceuticals Corp at BIO Investor Forum
Oct 1, 2014
Tekmira Pharmaceuticals Corp at Leerink Rare Disease Roundtable
Sep 22, 2014
Tekmira Pharmaceuticals Corp at Maxim Group's Institutional NYC BioDefense Mini-Conference
More events from DailyFinance »    

Address

Suite 100, 8900 Glenlyon Parkway
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Its product candidates include TKM-HBV, TKM-PLK1, TKM-Ebola and TKM-Marburg. TKM-HBV is an RNAi therapeutic for the treatment of Hepatitis B infection. The Company�s lead oncology product candidate, TKM -PLK1 is an oncology product platform that targets polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. TKM-ALDH2 is an application of RNAi for alcohol use disorder with a target patient population who have moderate to severe alcohol use disorder. TKM-Ebola is an anti-Ebola viral therapeutic being developed under a contract with the United States Department of Defense Joint Project Manager Medical Countermeasure Systems. TKM-Marburg is used to treat hemorrhagic fever viral infections.

Officers and directors

Daniel L. Kisner M.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Ian MacLachlan Ph.D. Executive Vice President, Chief Technical Officer
Age: 50
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 57
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 59
Bio & Compensation  - Reuters
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
Bio & Compensation  - Reuters
R. Hector MacKay-Dunn QC Corporate Secretary
Bio & Compensation  - Reuters
Peggy V. Phillips Director
Age: 60
Bio & Compensation  - Reuters
Donald G. Jewell Independent Director
Age: 60
Bio & Compensation  - Reuters